Preclinical News and Research

RSS

Tissue inflammation altered by “natural killer” immune cells

The discovery of a previously unknown role of “natural killer” (NK) immune cells by Melbourne researchers has increased the current understanding of how the immune system is controlled to prevent disease.

13 Feb 2023

Innovative cancer therapy options with new cell death mechanism

Researchers from The University of Texas MD Anderson Cancer Center have described a previously unrecognized type of cell death called disulfidptosis in a study that was published in Nature Cell Biology.

7 Feb 2023

Antibody that blocks VEGF-B could be a potential therapeutic option for fatty liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases.

6 Feb 2023

Employing molecular anchor for more effective CAR immunotherapies

Researchers at St. Jude Children’s Research Hospital discovered that immune cells with the attached protein boosted the killing of cancer, irrespective of the kind of cancer cell or the type of cancer being targeted.

3 Feb 2023

Clinically approved fungal vaccine protects against fungal infections

A new vaccine developed by the University of Georgia might be the first clinically approved immunization to safeguard against invasive fungal infections, which are becoming more common as antifungal drug resistance grows.

From University of Georgia 1 Feb 2023

Tumor progression after immunotherapy: Molecular pathways revealed

The University of Michigan’s Rogel Cancer Center researchers discovered a mechanism that explains why a subset of patients’ tumors grows rather than shrink when treated with immunotherapy.

20 Jan 2023

Using CRISPR technology to reduce the symptoms of Huntington’s disease

A neurological condition called Huntington's disease (HD) results in a progressive decline in movement, coordination, and mental ability. It is brought on by a mutation in the huntingtin, or HTT, gene.

From UC San Diego 14 Dec 2022

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

New 3D organoid model reveals a possible biological target for treating GEJ cancers

Researchers at Johns Hopkins Medicine say they have created a laboratory-grown three-dimensional "organoid" model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction (GEJ) — the point where the digestive system's food tube meets the stomach.

2 Dec 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

AXT Bring Novel Photoacoustic Imaging Technology to Australian Medical Researchers

AXT is pleased to announce a further expansion to their preclinical imaging portfolio with the addition of Luxonus

From AXT Pty Ltd 15 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

Potential therapeutic strategy for medulloblastoma relapse

Medulloblastoma, a kind of malignant brain tumor, can develop resistance to therapy, resulting in relapse. Uppsala University scientists found a protein that causes tumor cells to rest and become insensitive to radiation treatment.

1 Nov 2022

New tool advances potential means to deliver gene therapy

Researchers from Johns Hopkins Medicine claim to have successfully “slid” genetic instructions into a cell and produced essential proteins that were lacking from those cells using a cell’s normal process for creating proteins.

1 Nov 2022

Metabolite from pomegranate to boost immune cells that fight tumors

Researchers from the Georg-Speyer-Haus in Frankfurt am Main, Germany, and Goethe University Frankfurt have succeeded in developing a new strategy for the treatment of colorectal cancer as part of an interdisciplinary initiative of the LOEWE Center Frankfurt Cancer Institute (FCI).

28 Oct 2022

A more efficient way to deliver gene therapies to the CNS

For gene therapy, the blood-brain barrier (BBB) poses a formidable obstacle. The BBB, which is made up of cells that are closely packed together, prevents poisons and pathogens from accessing brain tissue while also blocking potential treatments for diseases that impact the CNS.

12 Oct 2022

A remarkable finding reorients attempts to cure liver disease

A long-running debate in gastroenterology has been settled by WEHI researchers who have shown that prevalent liver diseases are not caused by inflammatory cell death as previously believed.

From Walter and Eliza Hall Institute of Medical Research (WEHI) 7 Oct 2022

Highly effective and safe Zika vaccine technology

Scientists from the University of California, Los Angeles (UCLA) have discovered a Zika vaccine technology that is very safe and effective in preclinical mouse models.

29 Sep 2022

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

A “stress test” with a previously unknown gene to revive the exhausted T cells

The task of battling cancer cells can fatigue T cells employed in immunotherapy treatments, or they could shut down once they penetrate tumors. Researchers at the Gladstone Institutes and UC San Francisco have strengthened the therapeutic cells’ resistance via a CRISPR-based edit on their genomes.

30 Aug 2022